Spyridon Papapetropoulos
Chief Executive Officer bei BIONOMICS LIMITED
Vermögen: 20 291 $ am 31.03.2024
Profil
Spyridon Papapetropoulos is the founder of Encephalos Life Sciences LLC.
He currently holds the position of President, Chief Executive Officer & Director at Bionomics Ltd.
since 2023 and Chairman at Lipocine, Inc. since 2022.
Previously, he served as the Chief Executive Officer of Swanbio Therapeutics Ltd.
and SwanBio Therapeutics, Inc. in 2019.
He also held the role of Independent Director at Adamas Pharmaceuticals LLC from 2020 to 2021 and Chief Development Officer, SVP & Head-Development at ACADIA Pharmaceuticals, Inc. from 2019 to 2020.
Prior to that, he was the Chief Medical Officer & Head-R&D at Cavion, Inc. from 2017 to 2019.
Currently, he is also the Chief Medical Officer at Vigil Neuroscience, Inc. since 2020.
Dr. Papapetropoulos obtained his doctorate degrees from the University of Patras and Semmelweis University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VIGIL NEUROSCIENCE, INC.
0,01% | 10.04.2023 | 4 000 ( 0,01% ) | 13 640 $ | 31.03.2024 |
LIPOCINE INC
0,02% | 10.05.2023 | 1 279 ( 0,02% ) | 6 651 $ | 31.03.2024 |
Aktive Positionen von Spyridon Papapetropoulos
| Unternehmen | Position | Beginn |
|---|---|---|
| LIPOCINE INC. | Chairman | 03.11.2022 |
| BIONOMICS LIMITED | Chief Executive Officer | 05.01.2023 |
Encephalos Life Sciences LLC
 Encephalos Life Sciences LLC Miscellaneous Commercial ServicesCommercial Services Encephalos Life Sciences LLC is a consulting firm that specializes in providing professional services to biotech and pharmaceutical companies. Clients can reach out to him for additional information. The American company was founded by Spyridon Papapetropoulos, a neurologist who aims to assist businesses in developing drugs related to neurology. | Founder | - |
Ehemalige bekannte Positionen von Spyridon Papapetropoulos
| Unternehmen | Position | Ende |
|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Chief Tech/Sci/R&D Officer | 04.01.2023 |
| ADAMAS PHARMACEUTICALS, INC. | Director/Board Member | 24.11.2021 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01.09.2020 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chief Executive Officer | 01.09.2019 |
Cavion, Inc.
 Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Corporate Officer/Principal | 01.04.2019 |
Ausbildung von Spyridon Papapetropoulos
| University of Patras | Doctorate Degree |
| Semmelweis University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| BIONOMICS LIMITED | Health Technology |
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
| Lipocine, Inc. | |
Swanbio Therapeutics Ltd.
 Swanbio Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Swanbio Therapeutics Ltd. engages in the research and experimental development of biotechnology. The company was founded on September 1, 2017 and is headquartered in London, the United Kingdom. | Commercial Services |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
Encephalos Life Sciences LLC
Encephalos Life Sciences LLC Miscellaneous Commercial ServicesCommercial Services Encephalos Life Sciences LLC is a consulting firm that specializes in providing professional services to biotech and pharmaceutical companies. Clients can reach out to him for additional information. The American company was founded by Spyridon Papapetropoulos, a neurologist who aims to assist businesses in developing drugs related to neurology. | Commercial Services |
